Prodotto dalla casa farmaceutica Eli Lilly, la compressa fa parte dei medicinali anti-obesità Glp-1, la stessa categoria di Ozempic e Wegovy

Lilly says Foundayo was approved to treat obesity and can lead to long-term weight loss, alongside diet and exercise.

The FDA approval of Eli Lilly's GLP-1 pill Foundayo comes nearly three months after Novo Nordisk's oral version of Wegovy hit the market.